Sorajja Paul, Ukaigwe Anene C
Center for Valve and Structural Heart Disease, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.
Ann Cardiothorac Surg. 2021 Jan;10(1):43-49. doi: 10.21037/acs-2020-mv-17.
Severe mitral regurgitation (MR) is associated with heart failure and impaired survival with an annual mortality risk in excess of 5% per year for unoperated patients. Despite availability of surgical mitral valve interventions, as many as half of all patients with severe MR do not receive interventions. Transcatheter edge-to-edge repair with MitraClip has been a revolutionary therapy for MR, with over 100,000 treated patients worldwide. The usage has also expanded to different challenging anatomies as well as tricuspid regurgitation. Additionally, other transcatheter edge-to-edge repair devices are being studied. The evolution of these devices as well as what to expect in the future will be discussed here.
重度二尖瓣反流（MR）与心力衰竭及生存率降低相关，对于未经手术治疗的患者，其年死亡率风险超过5%。尽管有外科二尖瓣干预措施，但仍有多达一半的重度MR患者未接受干预。使用MitraClip进行经导管缘对缘修复已成为MR的一种革命性治疗方法，全球有超过10万名患者接受了治疗。其应用范围也已扩展到不同的复杂解剖结构以及三尖瓣反流。此外，其他经导管缘对缘修复装置也在研究中。本文将讨论这些装置的发展以及未来的展望。
